Apart from this new insight into how to define residual disease, an advantage of the PM-MRD approach is that it circumvents most subjective elements of MRD identification, while less experience is required to define CD34+, CD117+, and CD133+ cells and aberrancies thereon than to define the extent to which normal bone marrow differentiation patterns have become aberrant in AML. This evidence concerns the gene CD34 and acute myeloid leukemia.